Edition:
United States

Takeda Pharmaceutical Co Ltd (TKPYY.PK)

TKPYY.PK on OTC Markets Group

27.60USD
22 Nov 2017
Change (% chg)

$-0.12 (-0.43%)
Prev Close
$27.72
Open
$27.77
Day's High
$27.77
Day's Low
$27.46
Volume
26,481
Avg. Vol
67,436
52-wk High
$29.15
52-wk Low
$19.96

Chart for

About

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases,... (more)
No analyst recommendations are available for .

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 31.69 15.46
EPS (TTM): -- -- --
ROI: -- 15.18 11.85
ROE: -- 16.59 15.83

BRIEF-U.S. FDA provides new drug safety communication on Takeda's gout drug

* U.S. FDA says preliminary results from a safety clinical trial show increased risk of heart-related death with Febuxostat (Uloric) versus Allopurinol

Nov 15 2017

BRIEF-TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ADCETRIS FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA

* TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA

Nov 14 2017

Takeda takes on Sanofi with new global dengue vaccine data

Takeda Pharmaceutical's experimental dengue vaccine has produced promising long-term results in clinical tests, boosting the Japanese company's global hopes for a product that will take on Sanofi's Dengvaxia.

Nov 06 2017

Takeda takes on Sanofi with new global dengue vaccine data

Nov 7 Takeda Pharmaceutical's experimental dengue vaccine has produced promising long-term results in clinical tests, boosting the Japanese company's global hopes for a product that will take on Sanofi's Dengvaxia.

Nov 06 2017

BRIEF-Takeda and HemoShear Therapeutics enter drug discovery partnership in liver diseases

* Takeda and HemoShear Therapeutics enter into exclusive drug discovery partnership in liver diseases

Oct 17 2017

BRIEF-Takeda gets FDA approval for ALUNBRIG 180 mg tablets

* Takeda announces FDA approval of ALUNBRIG (brigatinib) 180 mg tablets

Oct 03 2017

BRIEF-Takeda, SGC in collaboration agreement related to inflammatory bowel disease

* Takeda and SGC announce a collaboration agreement using patient tissue-based assays for clinical target validation in inflammatory bowel disease

Sep 28 2017

Fujifilm says aims to spend $4.5 billion on M&A over three years

TOKYO Fujifilm Holdings Corp said it aimed to spend 500 billion yen ($4.54 billion) in strategic acquisitions over three years as it seeks growth outside its traditional photographic film business, which has been shrinking.

Aug 30 2017

Fujifilm says aims to spend $4.5 bln on M&A over 3 years

TOKYO, Aug 30 Fujifilm Holdings Corp said it aimed to spend 500 billion yen ($4.54 billion) in strategic acquisitions over three years as it seeks growth outside its traditional photographic film business, which has been shrinking.

Aug 30 2017

AstraZeneca strikes $400 million Parkinson's drug deal with Takeda

LONDON AstraZeneca is to receive up to $400 million from Takeda Pharmaceutical after striking a deal for the Japanese company to co-develop an early-stage medicine for Parkinson's disease.

Aug 29 2017

Earnings vs. Estimates

No consensus analysis data available.